Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone

The nonsteroidal mineralocorticoid receptor (MR) blocker esaxerenone has demonstrated good antihypertensive activity in a variety of patients, including those with uncomplicated grade I–III hypertension, hypertension with moderate renal dysfunction, hypertension with type 2 diabetes mellitus with al...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakugi, Hiromi, Yamakawa, Satoru, Sugimoto, Kotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019656/
https://www.ncbi.nlm.nih.gov/pubmed/33214722
http://dx.doi.org/10.1038/s41440-020-00569-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019656/
https://www.ncbi.nlm.nih.gov/pubmed/33214722
http://dx.doi.org/10.1038/s41440-020-00569-y

Ejemplares similares